If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Subscribe To Our Newsletter & Stay Updated
